Ruimin Hong

655 total citations
29 papers, 355 citations indexed

About

Ruimin Hong is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Ruimin Hong has authored 29 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Hematology. Recurrent topics in Ruimin Hong's work include CAR-T cell therapy research (24 papers), Virus-based gene therapy research (7 papers) and Viral Infectious Diseases and Gene Expression in Insects (6 papers). Ruimin Hong is often cited by papers focused on CAR-T cell therapy research (24 papers), Virus-based gene therapy research (7 papers) and Viral Infectious Diseases and Gene Expression in Insects (6 papers). Ruimin Hong collaborates with scholars based in China, France and South Korea. Ruimin Hong's co-authors include He Huang, Yongxian Hu, Houli Zhao, Guoqing Wei, Yiyun Wang, Linqin Wang, Linghui Zhou, Yongxian Hu, Fang Ni and Mingming Zhang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Ruimin Hong

25 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruimin Hong China 9 283 127 75 72 60 29 355
Houli Zhao China 10 275 1.0× 100 0.8× 66 0.9× 75 1.0× 50 0.8× 24 338
Edward Waldron United States 5 291 1.0× 160 1.3× 63 0.8× 73 1.0× 64 1.1× 13 362
Jiazhen Cui China 11 312 1.1× 139 1.1× 118 1.6× 76 1.1× 79 1.3× 39 423
Viktoria Blumenberg Germany 10 304 1.1× 61 0.5× 51 0.7× 72 1.0× 57 0.9× 32 361
Yaohui Wu China 9 263 0.9× 120 0.9× 63 0.8× 80 1.1× 68 1.1× 26 379
Reyisa Bughda United Kingdom 6 243 0.9× 114 0.9× 87 1.2× 39 0.5× 76 1.3× 9 313
Vania Baldan United Kingdom 6 294 1.0× 109 0.9× 144 1.9× 72 1.0× 83 1.4× 9 360
Chunrong Tong China 11 337 1.2× 108 0.9× 113 1.5× 86 1.2× 69 1.1× 50 450
Monalisa Ghosh United States 9 170 0.6× 87 0.7× 63 0.8× 26 0.4× 56 0.9× 45 308
Paul Castillo United States 9 331 1.2× 130 1.0× 154 2.1× 100 1.4× 130 2.2× 34 462

Countries citing papers authored by Ruimin Hong

Since Specialization
Citations

This map shows the geographic impact of Ruimin Hong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruimin Hong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruimin Hong more than expected).

Fields of papers citing papers by Ruimin Hong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruimin Hong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruimin Hong. The network helps show where Ruimin Hong may publish in the future.

Co-authorship network of co-authors of Ruimin Hong

This figure shows the co-authorship network connecting the top 25 collaborators of Ruimin Hong. A scholar is included among the top collaborators of Ruimin Hong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruimin Hong. Ruimin Hong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Rongrong, Shan Fu, Yang D. Teng, et al.. (2025). Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma. Journal for ImmunoTherapy of Cancer. 13(3). e010687–e010687. 2 indexed citations
2.
Zhang, Siqi, Jianfeng Zeng, Guofang Deng, et al.. (2025). Identification and evaluation of blood transcriptional biomarker for tuberculosis screening. International Journal of Infectious Diseases. 153. 107838–107838.
3.
Yang, Tingting, Rongrong Chen, Ruimin Hong, et al.. (2025). Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Bone Marrow Transplantation. 60(11). 1445–1450. 1 indexed citations
4.
Yang, Tingting, Yetian Dong, Mingming Zhang, et al.. (2025). Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia. Experimental Hematology and Oncology. 14(1). 2–2. 3 indexed citations
5.
Yang, Tingting, Yetian Dong, Mingming Zhang, et al.. (2024). Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 2818–2818. 1 indexed citations
6.
Huang, He, Yongxian Hu, Guoqing Wei, et al.. (2024). OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS).. Journal of Clinical Oncology. 42(16_suppl). 7511–7511. 7 indexed citations
7.
8.
Zhang, Mingming, Yongxian Hu, Guoqing Wei, et al.. (2024). Rituximab, Lenalidomide, and Zanubrutinib (ZR2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma. Blood. 144(Supplement 1). 91–91. 1 indexed citations
9.
Yu, Jinglei, Mingming Zhang, Jingjing Feng, et al.. (2024). A rare KMT2A::CBL transcript in an acute monoblastic leukemia patient with an unfavorable outcome. Molecular Biology Reports. 51(1). 561–561.
10.
Li, Wenxiao, Yongxian Hu, Mingming Zhang, et al.. (2024). APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial. Blood. 144(Supplement 1). 7229–7229. 1 indexed citations
11.
12.
Hu, Yongxian, Fang Ni, Zhongli Yang, et al.. (2022). CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nature Communications. 13(1). 5313–5313. 90 indexed citations
13.
Hu, Yongxian, Tianning Gu, Linqin Wang, et al.. (2022). CAR T-cell therapies in China: rapid evolution and a bright future. The Lancet Haematology. 9(12). e930–e941. 32 indexed citations
14.
Wang, Linqin, Ruimin Hong, Linghui Zhou, et al.. (2022). Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor–T-cell therapy. Cytotherapy. 25(2). 192–201. 6 indexed citations
15.
Hong, Ruimin, Yongxian Hu, & He Huang. (2021). Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction. Frontiers in Immunology. 12. 627764–627764. 33 indexed citations
16.
Zhou, Linghui, Houli Zhao, Yang Shao, et al.. (2021). Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment. Journal of Cancer. 12(18). 5423–5431. 12 indexed citations
17.
Wang, Yiyun, Linqin Wang, Yifan Zeng, et al.. (2021). Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission. Frontiers in Oncology. 11. 755584–755584. 6 indexed citations
18.
Hong, Ruimin, Linqin Wang, Xin Zhao, et al.. (2021). Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma. Frontiers in Oncology. 11. 713577–713577. 35 indexed citations
19.
Wang, Linqin, Ruimin Hong, Linghui Zhou, et al.. (2021). New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Frontiers in Oncology. 11. 702644–702644. 34 indexed citations
20.
Hong, Ruimin, Houli Zhao, Yiyun Wang, et al.. (2020). Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation. 56(3). 570–580. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Houli Zhao Breakdown of academic impact, for papers by Edward Waldron Breakdown of academic impact, for papers by Jiazhen Cui Breakdown of academic impact, for papers by Viktoria Blumenberg Breakdown of academic impact, for papers by Yaohui Wu Breakdown of academic impact, for papers by Reyisa Bughda Breakdown of academic impact, for papers by Vania Baldan Breakdown of academic impact, for papers by Chunrong Tong Breakdown of academic impact, for papers by Monalisa Ghosh Breakdown of academic impact, for papers by Paul Castillo
Rankless by CCL
2026